Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

M. A. Altinoz; S. Guloksuz; I. Elmaci

doi:10.1007/s12094-017-1613-6

Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

M. A. Altinoz^*, S. Guloksuz, I. Elmaci

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.

Original language	English
Pages (from-to)	785-792
Number of pages	8
Journal	Clinical & Translational Oncology
Volume	19
Issue number	7
DOIs	https://doi.org/10.1007/s12094-017-1613-6
Publication status	Published - Jul 2017

Keywords

Rabies virus
Cancer
Spontaneous remission
Immunotherapy
NERVOUS-SYSTEM
GLYCOPROTEIN
CLEARANCE
DELIVERY
RECEPTOR
THERAPY
SIRNA
RVG

Access to Document

10.1007/s12094-017-1613-6

Cite this

@article{31486d78e20f4eafb84a88222f30c355,

title = "Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential",

abstract = "To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.",

keywords = "Rabies virus, Cancer, Spontaneous remission, Immunotherapy, NERVOUS-SYSTEM, GLYCOPROTEIN, CLEARANCE, DELIVERY, RECEPTOR, THERAPY, SIRNA, RVG",

author = "Altinoz, {M. A.} and S. Guloksuz and I. Elmaci",

year = "2017",

month = jul,

doi = "10.1007/s12094-017-1613-6",

language = "English",

volume = "19",

pages = "785--792",

journal = "Clinical & Translational Oncology",

issn = "1699-048X",

publisher = "Springer",

number = "7",

}

TY - JOUR

T1 - Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma

T2 - new studies may resurrect a neglected potential

AU - Altinoz, M. A.

AU - Guloksuz, S.

AU - Elmaci, I.

PY - 2017/7

Y1 - 2017/7

N2 - To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.

AB - To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.

KW - Rabies virus

KW - Cancer

KW - Spontaneous remission

KW - Immunotherapy

KW - NERVOUS-SYSTEM

KW - GLYCOPROTEIN

KW - CLEARANCE

KW - DELIVERY

KW - RECEPTOR

KW - THERAPY

KW - SIRNA

KW - RVG

U2 - 10.1007/s12094-017-1613-6

DO - 10.1007/s12094-017-1613-6

M3 - (Systematic) Review article

C2 - 28093702

SN - 1699-048X

VL - 19

SP - 785

EP - 792

JO - Clinical & Translational Oncology

JF - Clinical & Translational Oncology

IS - 7

ER -